
ICU Medical (ICUI) Stock Forecast & Price Target
ICU Medical (ICUI) Analyst Ratings
Bulls say
ICU Medical is well-positioned for long-term success with its strong market position, diverse product portfolio, and strategic acquisitions. The company's solid financials, including a debt-to-equity ratio of 0.26 and a 5-year revenue growth rate of 24.45%, further support a positive outlook for investors. Additionally, ICU's focus on expanding their international presence and investing in new product development further strengthens their potential for growth in the future.
Bears say
ICU Medical is expected to face margin pressure in the coming years due to ongoing integration risks related to the recent acquisitions of Hospira and Smiths Medical, along with potential execution risks tied to the ongoing Smiths Medical integration. Additionally, the company's growth may be hindered by the completion of the U.S. plant consolidations and the shrinking of the competitive window before the replacement cycle accelerates in 2026. Furthermore, the potential separation of Vital Care could be accretive to revenue growth and margins, but the company continues to face risks related to the divestiture or sale of these products.
This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.
ICU Medical (ICUI) Analyst Forecast & Price Prediction
Start investing in ICU Medical (ICUI)
Order type
Buy in
Order amount
Est. shares
0 shares